CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $714 | +2.7% | 14,514 | +17.3% | 0.00% | -33.3% |
Q2 2023 | $695 | +24.1% | 12,372 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $560 | -24.3% | 12,372 | -32.0% | 0.00% | -25.0% |
Q4 2022 | $740 | -99.9% | 18,207 | 0.0% | 0.00% | -42.9% |
Q3 2022 | $1,190,000 | +183.3% | 18,207 | +163.2% | 0.01% | +250.0% |
Q2 2022 | $420,000 | -3.2% | 6,917 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $434,000 | -17.2% | 6,917 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $524,000 | -32.3% | 6,917 | 0.0% | 0.00% | -33.3% |
Q3 2021 | $774,000 | -30.9% | 6,917 | 0.0% | 0.00% | -40.0% |
Q2 2021 | $1,120,000 | +32.9% | 6,917 | 0.0% | 0.01% | +25.0% |
Q1 2021 | $843,000 | -20.4% | 6,917 | 0.0% | 0.00% | -20.0% |
Q4 2020 | $1,059,000 | +82.9% | 6,917 | 0.0% | 0.01% | +66.7% |
Q3 2020 | $579,000 | +14.0% | 6,917 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $508,000 | – | 6,917 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |